- HK$195.60m
- HK$553.25m
- HK$382.09m
- 24
- 60
- 21
- 22
Annual balance sheet for PuraPharm, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 91.4 | 59.7 | 75.8 | 20.1 | 12.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 222 | 300 | 156 | 113 | 88.7 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 608 | 611 | 486 | 350 | 268 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 554 | 492 | 431 | 397 | 355 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,375 | 1,206 | 1,016 | 844 | 716 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 592 | 665 | 665 | 571 | 491 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 863 | 804 | 758 | 691 | 605 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 512 | 402 | 258 | 153 | 111 |
| Total Liabilities & Shareholders' Equity | 1,375 | 1,206 | 1,016 | 844 | 716 |
| Total Common Shares Outstanding |